Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis
The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis. Results of this study may be pooled with the results of a separate study being conducted in participants with inflammatory bowel disease (Protocol GS-US-418-4279; NCT03201445) with the same objective.
Age
21 - 65 years
Sex
MALE
Healthy Volunteers
No
Medical center Medconsult Pleven OOD
Pleven, Bulgaria
UMHAT Pulmed OOD
Plovdiv, Bulgaria
UMHAT Sv. Georgi, EAD
Plovdiv, Bulgaria
MHAT "Eurohospital" - Plovdiv, OOD
Plovdiv, Bulgaria
Medical Center Teodora, EOOD
Rousse, Bulgaria
Medizinski Zentar-1-Sevlievo EOOD
Sevlievo, Bulgaria
Medical Center Excelsior, OOD
Sofia, Bulgaria
DCC Alexandrovska, EOOD
Sofia, Bulgaria
UMHAT Sv. Ivan Rilski, EAD
Sofia, Bulgaria
DCC 17 - Sofia EOOD
Sofia, Bulgaria
Start Date
May 28, 2019
Primary Completion Date
August 14, 2020
Completion Date
May 10, 2023
Last Updated
April 30, 2024
109
ACTUAL participants
Filgotinib
DRUG
Placebo
DRUG
Standard of Care
DRUG
Lead Sponsor
Galapagos NV
Collaborators
NCT07295509
NCT07484243
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06647069